Get the Stockscreener App
9.34
0.69%
-0.07
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $9.34, with a volume of 1.19M.
It is down -0.69% in the last 24 hours and up +3.72% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$9.41
Open:
$9.38
24h Volume:
1.19M
Relative Volume:
0.09
Market Cap:
$10.97B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-2.9464
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
+5.00%
1M Performance:
+3.72%
6M Performance:
-16.56%
1Y Performance:
-22.64%
1-Day Range:
$9.225
$9.38
1-Week Range:
$8.895
$9.42
52-Week Range:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
9.35 | 11.04B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
152.43 | 67.73B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.34 | 45.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.755 | 44.38B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.48 | 18.97B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.46 | 13.73B | 2.99B | 1.21B | 1.13B | 25.06 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
What data driven models say about Viatris Inc.’s futureDaily Market Momentum and Pressure Analysis - Newser
US Court Agrees To Throw Out Viatris Wegovy Infringement Case - insights.citeline.com
How to interpret RSI for Viatris Inc. stockMomentum Stocks with Breakout Potential - Newser
Why Viatris Inc. stock attracts strong analyst attention Daily Trade Monitor with Pattern Alerts - Newser
Why is Viatris Inc. stock attracting strong analyst attentionInvest in high-yield stocks with confidence - jammulinksnews.com
How does Viatris Inc. compare to its industry peersFree Bull & Bear Market Updates - jammulinksnews.com
How volatile is Viatris Inc. stock compared to the marketUnprecedented profit potential - jammulinksnews.com
Why Viatris Inc. stock attracts strong analyst attentionSmart High Yield Swing Trades - metal.it
What analysts say about Viatris Inc. stockTremendous wealth creation - PrintWeekIndia
What drives Viatris Inc. stock priceMarket-crushing profits - PrintWeekIndia
What institutions are buying Viatris Inc. stock nowUnprecedented growth rates - jammulinksnews.com
Bausch Health adds two pharmaceutical industry veterans to board By Investing.com - Investing.com Nigeria
Bausch Health Expands Leadership: Ex-Viatris CEO and Bristol Myers Legal Chief Join Board in Strategic Move - Stock Titan
Novo Nordisk defeated in Wegovy patent dispute by Viatris - Yahoo Finance
Is Viatris Inc. a good long term investmentOutperformance with explosive growth - Autocar Professional
Novo Nordisk loses Wegovy patent fight against generics maker Viatris - Endpoints News
Viatris’ Wegovy Copy Sheds One Novo Patent in Delaware Lawsuit - Bloomberg Law News
Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha
What to Expect From Viatris' Next Quarterly Earnings Report - MSN
What To Expect From Viatris' Next Quarterly Earnings Report - Barchart.com
VTRS Down on Late-Stage Study Failure of Eye Disease Drug - MSN
Viatris down on late-stage trial setback for eye disorder therapy - MSN
Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq
Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance
Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter
Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com
Viatris Announces Disappointing Phase 3 Study Results for MR-139 in Blepharitis, But Continues to Focus on Delivering Novel Therapies. - AInvest
Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest
Trend Tracker for (VTRS) - news.stocktradersdaily.com
Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest
Viatris stock unchanged as Goldman maintains Neutral rating on trial miss By Investing.com - Investing.com South Africa
Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target - TradingView
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review - Benzinga
Why Viatris (VTRS) Stock Is Falling Today - Yahoo Finance
Viatris stock unchanged as Goldman maintains Neutral rating on trial miss - Investing.com
Viatris Shares Dip After Blepharitis Treatment Fails to Hit Main Study Goal - MSN
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target - Barron's
Viatris' Resilience in Ophthalmology: Navigating Setbacks and Strategic Growth - AInvest
Why Is Viatris Stock Falling In Pre-market? - Nasdaq
Viatris stock down on late-stage trial setback (VTRS:NASDAQ) - Seeking Alpha
Viatris eye ointment fails late-stage study, shares fall - TradingView
Viatris stock falls after Phase 3 blepharitis study misses endpoint - Investing.com
Viatris' Strategic Resilience Amid Clinical Setbacks: Diversification as a Path to Ophthalmology Growth - AInvest
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):